2025-01-26 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**1. Performance Comparison & Overview:**

Johnson & Johnson is a multinational corporation that manufactures medical devices, pharmaceuticals, and consumer packaged goods.

The cumulative return of JNJ (25.31%) significantly lags behind the S&P 500 (VOO) cumulative return (122.16%) over the analyzed period.  The difference is -96.8%, placing it at the 1.9th percentile of the historical range of divergence between JNJ and the S&P 500 (based on the provided min and max divergence). This indicates JNJ's underperformance relative to the broader market.  The consistently negative alpha values across the provided years further support this underperformance relative to the benchmark.

**Alpha and Beta Analysis:**  The provided data shows consistently low and negative alpha values, indicating that JNJ has not generated excess returns compared to the market (represented by the beta). The beta values fluctuate but generally remain around 0.0, implying low sensitivity to market movements.  The substantial variations in CAGR (Compound Annual Growth Rate) and MDD (Maximum Drawdown) across different periods highlight the volatility in JNJ's performance. The company's market capitalization (Cap(B)) shows consistent growth over the period.

**2. Recent Price Movement:**

* **Closing Price:** $146.82
* **5-Day Moving Average:** $146.78
* **20-Day Moving Average:** $145.14
* **60-Day Moving Average:** $149.80

The price is slightly above the 5-day and 20-day moving averages but below the 60-day moving average, suggesting a potential short-term upward trend but a longer-term downward trend since the 60-day MA is higher.  The recent price change is positive but small (0.12$), indicating relatively low volatility in the very short term.


**3. Technical Indicators & Expected Return:**

* **RSI (Relative Strength Index):** 57.20 -  Suggests neither overbought nor oversold conditions; the market is relatively neutral.
* **PPO (Percentage Price Oscillator):** 0.40 - A positive value suggests a bullish momentum.
* **20-Day Relative Divergence:** -5.6% - Indicates a recent short-term bearish trend.
* **Expected Return:** -1481.7% - This extremely negative expected return relative to the S&P 500 over the long term is concerning and needs further investigation.  The methodology for calculating this figure is not provided and requires clarification. It's likely an error.

**4. Recent Earnings Analysis:**

| Date       | EPS      | Revenue       |
|------------|----------|---------------|
| 2024-10-23 | $1.12    | $22.47B       |
| 2024-07-25 | $1.95    | $22.45B       |
| 2024-05-01 | $1.35    | $21.38B       |
| 2024-02-16 | $1.68    | $21.39B       |
| 2023-10-27 | $10.32   | $21.35B       |

EPS shows significant volatility, with a dramatic spike in Q4 2023. Revenue remains relatively stable.  Further analysis is needed to understand the reasons behind the EPS fluctuation.  The unusually high EPS in Q4 2023 requires detailed investigation to determine if it represents an exceptional event or an accounting anomaly.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2024-09-30 | $22.47B | 69.01%       |
| 2024-06-30 | $22.45B | 69.40%       |
| 2024-03-31 | $21.38B | 69.55%       |
| 2023-12-31 | $21.39B | 68.23%       |
| 2023-09-30 | $21.35B | 69.06%       |

Revenue is relatively stable. Profit margins are consistently high but show slight fluctuations.


**Capital and Profitability:**

| Quarter | Equity   | ROE     |
|---------|----------|---------|
| 2024-09-30 | $70.16B | 3.84%  |
| 2024-06-30 | $71.54B | 6.55%  |
| 2024-03-31 | $70.02B | 4.65%  |
| 2023-12-31 | $68.77B | 5.89%  |
| 2023-09-30 | $71.23B | 36.54% |


Equity shows some fluctuation. ROE is highly volatile, with an unusually high value in Q3 2023. This requires further investigation to understand the underlying causes.


**7. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 over the period analyzed. While showing relatively stable revenue and high profit margins, the company's earnings per share (EPS) and return on equity (ROE) exhibit considerable volatility.  The -1481.7% expected return needs serious scrutiny and is likely a data error. The consistently negative alpha suggests JNJ has not delivered excess returns compared to the market.  The unusual spike in EPS in Q4 2023 and the high ROE in Q3 2023 require further investigation to identify the contributing factors.  Before making any investment decisions, a thorough review of JNJ's financial statements and an understanding of the unusual fluctuations in key financial metrics are crucial.  The provided data alone does not support a strong investment recommendation.


**8. Disclaimer:** This analysis is based on the limited data provided.  It is not financial advice.  Conduct thorough due diligence and consult with a financial professional before making any investment decisions.
